| Identification | Back Directory | [Name]
E 6130 | [CAS]
1427058-33-0 | [Synonyms]
E 6130
E-6130,E6130
3-Pyrrolidineacetic acid, 1-[[2-chloro-6-(trifluoromethyl)phenyl]methyl]-3-[[[1-(1-cyclohexen-1-ylmethyl)-4-piperidinyl]amino]carbonyl]-4-methyl-, (3S,4R)- | [Molecular Formula]
C28H37ClF3N3O3 | [MDL Number]
MFCD31657359 | [MOL File]
1427058-33-0.mol | [Molecular Weight]
556.06 |
| Chemical Properties | Back Directory | [Boiling point ]
649.2±55.0 °C(Predicted) | [density ]
1.31±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: ≥ 250 mg/mL (449.59 mM) | [form ]
Solid | [pka]
4.43±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
E6130 is an orally active and highly selective CX3CR1 modulator, that may be effective for treatment of inflammatory bowel disease. | [in vivo]
E6130 (10 or 30 mg/kg, p.o.) reduces several inflammatory bowel disease-related parameters in a murine CD4+ CD45RBhigh T-cell-transfer colitis model and a murine oxazolone-induced colitis model[1]. | [References]
[1] Wakita H, et al. E6130, a Novel CX3C Chemokine Receptor 1 (CX3CR1) Modulator, Attenuates Mucosal Inflammation and Reduces CX3CR1+ Leukocyte Trafficking in Mice with Colitis. Mol Pharmacol. 2017 Nov;92(5):502-509. DOI:10.1124/mol.117.108381 |
|
|